These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25171595)

  • 1. Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy.
    Konarzewski M; Szolkiewicz M; Sucajtys-Szulc E; Blaszak J; Lizakowski S; Swierczynski J; Rutkowski B
    Am J Nephrol; 2014; 40(2):157-63. PubMed ID: 25171595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels.
    Abujrad H; Mayne J; Ruzicka M; Cousins M; Raymond A; Cheesman J; Taljaard M; Sorisky A; Burns K; Ooi TC
    Atherosclerosis; 2014 Mar; 233(1):123-9. PubMed ID: 24529132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism.
    Morena M; Le May C; Chenine L; Arnaud L; Dupuy AM; Pichelin M; Leray-Moragues H; Chalabi L; Canaud B; Cristol JP; Cariou B
    J Clin Lipidol; 2017; 11(1):87-93. PubMed ID: 28391915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration.
    Miyazawa H; Honda T; Miyauchi S; Domon H; Okui T; Nakajima T; Tabeta K; Yamazaki K
    Clin Chim Acta; 2012 Jan; 413(1-2):154-9. PubMed ID: 22001517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 in chronic kidney disease.
    Pavlakou P; Liberopoulos E; Dounousi E; Elisaf M
    Int Urol Nephrol; 2017 Jun; 49(6):1015-1024. PubMed ID: 28084558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants.
    Araki S; Suga S; Miyake F; Ichikawa S; Kinjo T; Yamamoto Y; Kusuhara K
    Early Hum Dev; 2014 Oct; 90(10):607-11. PubMed ID: 25134067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR.
    Rogacev KS; Heine GH; Silbernagel G; Kleber ME; Seiler S; Emrich I; Lennartz S; Werner C; Zawada AM; Fliser D; Böhm M; März W; Scharnagl H; Laufs U
    PLoS One; 2016; 11(1):e0146920. PubMed ID: 26799206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
    Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects.
    Lambert G; Petrides F; Chatelais M; Blom DJ; Choque B; Tabet F; Wong G; Rye KA; Hooper AJ; Burnett JR; Barter PJ; Marais AD
    J Am Coll Cardiol; 2014 Jun; 63(22):2365-73. PubMed ID: 24632287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.
    Zhang Y; Xu RX; Li S; Zhu CG; Guo YL; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):426-33. PubMed ID: 25770756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
    Nozue T; Hattori H; Ishihara M; Iwasaki T; Hirano T; Kawashiri MA; Yamagishi M; Michishita I
    Am J Cardiol; 2013 May; 111(10):1415-9. PubMed ID: 23433768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure.
    Sucajtys-Szulc E; Szolkiewicz M; Swierczynski J; Rutkowski B
    Mol Cell Biochem; 2016 Jan; 411(1-2):281-7. PubMed ID: 26481479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of estrogen on serum level and hepatocyte expression of PCSK9.
    Guo W; Fu J; Chen X; Gao B; Fu Z; Fan H; Cui Q; Zhu X; Zhao Y; Yang T; Fan D; Zhou H
    Metabolism; 2015 Apr; 64(4):554-60. PubMed ID: 25665485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
    Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
    Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.